Research and Development

Valeant has announced that the US Food and Drug Administration’s (FDA) dermatologic and ophthalmic drugs advisory committee has recommended brodalumab …

Celgene has entered into a collaboration with Jounce Therapeutics that will see the pair jointly develop and commercialise Jounce’s lead …

Bristol-Myers Squibb has announced that its lead oncology drug, Opdivo (nivolumab), is set to go before regulators in the US …

Novartis has warned that its profits may decline this year as it issued second quarter results, with generic competition for …

ViiV Healthcare has presented late-stage data showing superior efficacy for combination treatment Triumeq (dolutegravir/abacavir/lamivudine) compared with atazanavir, plus other treatments, …

AstraZeneca has presented results from the latest Phase III trial evaluating Tagrisso (osimertinib) as a second line treatment for patients …

Roche has announced that a Phase III trial evaluating Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated diffuse large B-cell lymphoma …

The European Medicines Agency (EMA) has accepted for review the marketing authorisation application from Samsung Bioepis for their biosimilar version …

Abbott has announced that the Tecnis Symfony Intraocular Lenses for the treatment of cataracts has been approved by the US …

Staff at the US Food and Drug Administration have expressed concerns over Valeant’s psoriasis candidate, brodalumab, due to the potential …

Ziopharm Oncology has issued a statement following the death of a patient enrolled on a Phase I clinical trial for …

UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy …

Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead …

The National Institute for Health and Care Excellence (Nice) rejected United Therapeutics’ (Nasdaq: UTHR) Unituxin (dinutuximab) in combination therapy to …

Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.